|
Yvonne
Paterson, Ph.D.
Professor, Dept of Microbiology
Microbiology,
Virology and Parasitology Program
and
Gene Therapy and Vaccines Program
Address
323 Johnson Pavilion (Lab)
3610 Hamilton Walk
Philadelphia, PA 19104
Office tel.: 215 898-3461
Lab tel.: 215 898-2145
Fax: 215 573-4666
E-mail: yvonne@mail.med.upenn.edu
Link(s)
Immunology
Graduate Group Faculty Page
Dept
of Microbiology Faculty Page
Education
University of Manchester, United Kingdom: B Sci Tech (Biochemistry), 1963.
University of Manchester, United Kingdom: MSc (Biochemistry), 1966.
Australian National University, Australia: BA (Math/Philosophy), 1969.
University of Melbourne, Australia: PhD (Biochemistry), 1979.
|
Research
Interests
- Rational approaches to immune intervention
in neoplastic and infectious disease.
Key words: Immune regulation, antigen
design, vaccine development, cancer immunotherapy, HIV, HPV.
Search PubMed for articles
Description
of Research
The research performed in the Paterson laboratory
is dedicated to harnessing the immune system to provide cures
for, or protection against, neoplastic and infectious disease.
There have been enormous advances made in the last few years
in our understanding of the molecular and cellular machinery
that renders proteins immunogenic. In our laboratory, we are
applying this knowledge to the development of strategies to
enhance the immune response in the design of more effective
vaccines against viral diseases, such as HIV, and against
tumor cells. To do this we are using a facultative intracellular
bacterium, Listeria monocytogenes, which has the unusual ability
to live and grow in the cytoplasm of the cell. Our laboratory
was the first to show that this bacterium could be used to
target antigens to the MHC class I pathway for antigen processing
with the induction of cytotoxic T cells and has pioneered
the application of this organism in vaccine development over
the past 15 years. We have shown that recombinant forms of
this organism which have been transformed to express viral
antigens from influenza, HIV and SIV are excellent vectors
for inducing cell mediated immune responses both parenterally
and at mucosal surfaces. We have also applied this technology
in the development of cancer vaccines that result in the induction
of potent cell mediated immunity that can eliminate established
macroscopic tumors even in the face of profound immune tolerance
to the tumor-associated antigen. In other studies, we have
discovered that fusing an antigen to some bacterial proteins
enhances its immunogenicity. This finding opens up novel,
and perhaps safer, avenues to cancer immunotherapy. We are
currently looking at a number of different approaches to carry
these fusion proteins to the immune system for cancer immunotherapy.
Cancers to which we are directing our various technologies
currently include cervical cancer, breast cancer, lung cancer,
melanoma and lymphoma.
Recent
Publications
Maciag, P and Y. Paterson. "Listeria-based vaccines for cancer treatment." Current Opinion in Molecular Therapeutics 7:454-460. 2005.
Peng X., Treml J. and Y. Paterson. Adjuvant properties of listeriolysin O protein in a DNA vaccination strategy. Cancer Immunol. Immunother. 56:797-806. 2007
Singh R., and Y. Paterson In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccines. Cancer Immunol Immunother. 56:927-38. 2007
Singh R., and Y. Paterson Immunoediting sculpts tumor epitopes during immunotherapy. Cancer Res. 67: 1887-92. 2007
Souders N.C., Sewell D.A., Pan Z.K., Hussain S.F., Rodriguez A., Wallecha A. and Y.Paterson. Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer. Cancer Immun. 7:2. 2007.
Lab
Rotation
Projects
- The role of the Listeria's hemolysin in initiating an immune response.
- Mechanisms of CTL Tumor Infiltration.
- Listeria based vaccines targeting HER-2/neu for cancer.
- Strategies to overcome tolerance to tumor antigens.
- Lab
personnel:
-
Anita Giacone - Administrative Coordinator
Patrick Guirnalda - Postdoctoral Fellow
Matt Seavey - Postdoctoral Fellow
Laurence Wood - Postdoctoral Fellow
Zhen-Kun Pan - Research Specialist
Marianne Rosario - Lab Assistant
last updated 1/2008
|
